HIMS

Hims & Hers Health (HIMS) declined 4.87% on October 23, 2026, underperforming the S&P 500's 0.52% loss. The company is expected to report earnings on November 9, 2026, with analysts forecasting $0.07 EPS (16.67% YoY growth) and $893.37M revenue (49.15% growth).

However, full-year estimates show -$0.79 EPS and $3.22B revenue. HIMS currently holds a Zacks Rank #3 (Hold) rating with no EPS estimate changes in the past 30 days.

A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made materially false statements regarding consumer health data sharing with third-party advertisers, premature prescription charges despite promises of provider consultation, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 are eligible to join the case.

Hims & Hers Health faces a securities class action lawsuit after the FTC alleged the telehealth provider shared consumers' sensitive health information with third-party advertising platforms while claiming to maintain privacy, and deceived users about billing and cancellation practices. The stock declined 14.73% on July 29, 2026, following the FTC announcement. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file lead plaintiff applications.

A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding consumer health data sharing with third-party advertising platforms, charging for prescriptions immediately after intake forms despite promising provider consultation, and failing to disclose regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to apply as lead plaintiff.

A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made false statements about consumer data privacy, misrepresented prescription charging practices, and failed to disclose regulatory risks. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 are encouraged to join the case.

Hims & Hers Health is approaching a three million member milestone, with several catalysts positioned to sustain robust growth. The company operates in the healthcare industry, which is described as ripe for disruption.

Rosen Law Firm is urging investors who purchased Hims & Hers Health securities between August 4, 2025 and July 29, 2026 to secure legal counsel before the November 2, 2026 lead plaintiff deadline. The class action lawsuit alleges that Hims made materially false statements regarding consumer health data sharing with third-party advertisers, premature prescription charges, and regulatory risks that were not properly disclosed to investors.

Rosen Law Firm has filed securities class action lawsuits against Millrose Properties, Hims & Hers Health, and Doximity for alleged disclosure failures and misleading statements to investors. Millrose Properties is accused of misrepresenting its business objectives and leasing properties at a loss. Investors have until December 8, 2026 to move the court to serve as lead plaintiff.

Rosen Law Firm announces a securities class action lawsuit against Hims & Hers Health, Inc. for allegedly making false statements about data privacy practices and billing procedures. The lawsuit claims Hims shared consumer health information with third-party advertisers and charged for prescriptions immediately despite promising consultations with medical providers.

Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.

Hims & Hers Health (HIMS) has attracted investor attention with a 5.3% return over the past month, outperforming the S&P 500. The company shows strong revenue growth of 49.2% year-over-year for the current quarter, but faces challenges with a Zacks Rank #3 (Hold) rating and a D valuation grade indicating premium pricing relative to peers. Earnings estimates remain unchanged over the last 30 days.

A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made materially false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 1, 2026.

Robbins Geller announces a class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' health information with third-party advertising platforms and charging for prescriptions immediately after intake forms despite claiming personalized consultations. The FTC filed a lawsuit on July 29, 2026, leading to a 15% decline in Hims & Hers stock. Investors with substantial losses can seek lead plaintiff status before November 2, 2026.

Robbins LLP is reminding investors of a pending class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' sensitive health information with advertising platforms while claiming privacy protection, and engaging in deceptive billing practices. The FTC filed a lawsuit on July 29, 2026, which caused HIMS stock to decline 14.73%. Investors who purchased securities between August 4, 2025 and July 29, 2026 may be eligible to participate, with a lead plaintiff deadline of November 2, 2026.

Hims & Hers Health (HIMS) declined 6.7% on October 14, 2026, significantly underperforming the S&P 500's 1.11% loss. Despite a 6.68% monthly gain, the stock faces upcoming earnings on November 9, 2026, with expectations of $0.07 EPS (up 16.67% YoY) and $893.37M revenue (up 49.15% YoY). The company holds a Zacks Rank #3 (Hold) rating with stagnant consensus estimates.

A class action securities fraud lawsuit has been filed against Hims & Hers Health, Inc. following an FTC lawsuit alleging the telehealth provider shared consumers' sensitive health information with third-party advertising platforms and engaged in deceptive billing practices. The stock declined 14.73% on July 29, 2026, following the FTC announcement. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file a lead plaintiff motion.

Hims & Hers Health has launched Hers, its women's health platform, in Australia by rebranding Juniper from its Eucalyptus acquisition. The platform offers personalized care for hair regrowth, menopause, and weight management with 24/7 support. The expansion leverages Eucalyptus' local presence to strengthen brand recognition and recurring revenue in the growing Australian telehealth market, which is projected to grow at 18.2% CAGR through 2034.

Rosen Law Firm has filed securities class action lawsuits against multiple companies. The primary case involves Hims & Hers Health, Inc., alleging the company made false statements about data privacy, charged consumers for prescriptions without proper consultation, and failed to disclose regulatory scrutiny.

The firm is seeking lead plaintiffs with a November 2, 2026 deadline. Similar lawsuits have been filed against Papa John's International and Millrose Properties.

A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false statements and failing to disclose that it shares consumers' health information with third-party advertising platforms and charges for prescriptions immediately after intake forms are submitted. The FTC, California, and Utah filed a separate lawsuit on July 29, 2026, resulting in a 14.73% stock price decline.

Rosen Law Firm is encouraging investors who purchased Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false and misleading statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, which subjected the company to potential fees and penalties.

Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company deceptively shared consumers' health data with third-party advertising platforms like Meta and Snap, and violated billing regulations by charging for prescriptions before medical consultations. The stock plunged 14.7% on July 29, 2026, erasing over $970 million in market value.